Redeye is encouraged by yesterday’s capital market day, which further emphasized that Egetis has a c...
’23e district heating prices raised by up to 20%...
Q3’22e EBIT of SEK 50m, down 2% y-o-y Estimates unchanged for 2022-2024 2023e EV/EBIT of 7x with 6...
Redeye makes changes to both the short- and long-term estimates on the back of a very strong quarter...
Redeye raises its forecasts and Base Case following Hexatronic’s preliminary Q3 figures beating our ...
Internal improvements offset by cautious customers Recession risk reflected in update, ‘23e EBIT do...
Redeye is positively surprised by the powerful Q3 report.
Redeye remains impressed by the rapid development of Vicore’s new generation of ATRAGs (angiotensin ...
Fram Skandinavien: Monthly NAV and Strong Revenue Growth for Carmudi
Vår vy är att både bolaget ABAS Protect, och deras stundande notering bjuder på ett intressant läge.
Lipigon aviserade nyligen positiva säkerhetsdata med Lipisense i fas 1-studiens första del (SAD).
Efter positiva studier från Eisab/Biogen med lecanemab mot Alzheimers sjukdom ser vi att caset för A...
Elanders will present its Q3 report on 17 October. We expect solid Q3 results, with a ~5% y/y increa...
We expect a sequential decline in Rovio's Games revenue for Q3 in the midst of mobile gaming market ...
Redeye discusses the initiation of the phase Ib clinical trial with Pulmostem.
CirChem meddelade den 10 oktober att de tecknat ännu ett avtal med Stena Recycling, vilket löper öve...
Redeye raises its Base Case of Infracom following the acquisition of Quality of Service as we includ...
Förannonserade Q3’22 försäljning och EBIT BE Group förannonserade den 10 oktober 2022 preliminära si...
Marknadssituationen har förändrats och risktagande premieras inte längre.
Redeye comments on Lifeclean’s decision to appoint David Johansson as the new interim CEO.
